UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

In vivo measurements of nasal airway dimensions and ultrafine aerosol deposition in the human nasal and oral airways

Journal of aerosol science, 1996-07, Vol.27 (5), p.785-801

1996

Volltextzugriff (PDF)

Deposition of Ultrafine Aerosols in the Head Airways During Natural Breathing and During Simulated Breath Holding Using Replicate Human Upper Airway Casts

Aerosol science and technology, 1995, Vol.23 (3), p.465-474

1995

Volltextzugriff (PDF)

Calculation of Total Deposition Fraction of Ultrafine Aerosols in Human Extrathoracic and Intrathoracic Regions

Aerosol science and technology, 1995-01, Vol.22 (2), p.194-201

1995

Volltextzugriff (PDF)

Deposition of Ultrafine Aerosols and Thoron Progeny in Replicas of Nasal Airways of Young Children

Aerosol science and technology, 1995, Vol.23 (4), p.541-552

1995

Volltextzugriff (PDF)

An Experimental Method for Measuring Aerosol Deposition Efficiency in the Human Oral Airway

American Industrial Hygiene Association journal, 1997-03, Vol.58 (3), p.207-213

1997

Volltextzugriff (PDF)

Application of both a physical theory and statistical procedure in the analyses of an in vivo study of aerosol deposition

Journal of aerosol science, 1996-06, Vol.27 (4), p.653-654

1996

Volltextzugriff (PDF)

In vivo measurements of nasal airway dimensions and deposition of ultrafine aerosols in the extrathoracic airways

Cheng, Kuo-Hsi

1996

Volltextzugriff (PDF)

Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

International journal of cancer, 2022-02, Vol.150 (4), p.626-635

2022

Volltextzugriff (PDF)

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Scientific reports, 2022-03, Vol.12 (1), p.4398-4398, Article 4398

2022

Volltextzugriff (PDF)

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Thoracic cancer, 2024-03, Vol.15 (7), p.529-537

2024

Volltextzugriff (PDF)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Thoracic cancer, 2020-06, Vol.11 (6), p.1541-1549

2020

Volltextzugriff (PDF)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Cancers, 2022-01, Vol.14 (3), p.674

2022

Volltextzugriff (PDF)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Scientific reports, 2023-11, Vol.13 (1), p.20323-20323, Article 20323

2023

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Thoracic cancer, 2023-01, Vol.14 (1), p.12-23

2023

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Thoracic cancer, 2022-07, Vol.13 (13), p.1888-1897

2022

Volltextzugriff (PDF)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Therapeutic advances in respiratory disease, 2022, Vol.16, p.175346662211327-17534666221132731

2022

Volltextzugriff (PDF)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

Thoracic cancer, 2023-02, Vol.14 (4), p.348-356

2023

Volltextzugriff (PDF)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib

Thoracic cancer, 2023-09, Vol.14 (25), p.2548-2557

2023

Volltextzugriff (PDF)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

Cancers, 2022-02, Vol.14 (4), p.977

2022

Volltextzugriff (PDF)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.175883592110357-17588359211035710

2021

Volltextzugriff (PDF)

Step-wise diagnostic approach for patients with uveitis - Experts consensus in Taiwan

Journal of microbiology, immunology and infection, 2022-08, Vol.55 (4), p.573-580

2022

Volltextzugriff (PDF)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Frontiers in oncology, 2023-10, Vol.13, p.1249106-1249106

2023

Volltextzugriff (PDF)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

Cancers, 2022-10, Vol.14 (20), p.5095

2022

Volltextzugriff (PDF)

Cryptococcus gattii Infection as the Major Clinical Manifestation in Patients with Autoantibodies Against Granulocyte–Macrophage Colony-Stimulating Factor

Journal of clinical immunology, 2022-11, Vol.42 (8), p.1730-1741

2022

Volltextzugriff (PDF)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic advances in medical oncology, 2022, Vol.14, p.175883592211132-17588359221113278

2022

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Aktive Filter

KollektionNexis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(102)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

In vivo measurements of nasal airway dimensions and ultrafine aerosol deposition in the human nasal and oral airways

Deposition of Ultrafine Aerosols in the Head Airways During Natural Breathing and During Simulated Breath Holding Using Replicate Human Upper Airway Casts

Calculation of Total Deposition Fraction of Ultrafine Aerosols in Human Extrathoracic and Intrathoracic Regions

Deposition of Ultrafine Aerosols and Thoron Progeny in Replicas of Nasal Airways of Young Children

An Experimental Method for Measuring Aerosol Deposition Efficiency in the Human Oral Airway

Application of both a physical theory and statistical procedure in the analyses of an in vivo study of aerosol deposition

In vivo measurements of nasal airway dimensions and deposition of ultrafine aerosols in the extrathoracic airways

Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Step-wise diagnostic approach for patients with uveitis - Experts consensus in Taiwan

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

Cryptococcus gattii Infection as the Major Clinical Manifestation in Patients with Autoantibodies Against Granulocyte–Macrophage Colony-Stimulating Factor

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Aktive Filter

Suchergebnisse filtern